BlueSphere Bio aims to overcome challenges in the CAR T space with a precision approach to T cell therapy.
BlueSphere CEO Dr. David Apelian, M.D., Ph.D/Courtesy BlueSphere Bio
One of the greatest recent innovations in cancer treatment, CAR T therapies have sent some patients into long-lasting remission, with speedier recoveries, due to the lack of aggressive chemotherapy involved. They are the darling of numerous biopharma companies, including Sorrento Therapeutics, Kite Pharma (Gilead), and Allogene Therapeutics.
But they still have their limitations. They can only target a single tumor-associated antigen, recognize only cell surface antigens, and are not wholly tumor-specific, only targeting proteins expressed by normal and malignant cells. Enter BlueSphere Bio, a small biotech aiming to overcome these challenges with a precision approach to T cell therapy.
Headquartered in Pittsburgh, Pa., and founded in 2018, BlueSphere has been operating under the radar. Not anymore. BioSpace sat down with Chief Executive Officer Dr. David Apelian, M.D., Ph.D., who shared why he believes the company’s TCXpress is the “premier T cell receptor platform” that can have a significant impact on cancer.
When Apelian spoke with Co-Founder and Chief Scientific Officer Dr. Mark Shlomchik, M.D., Ph.D., about technology he was developing that could rapidly screen and capture thousands of T cell receptors from the sample more efficiently and cost-effectively than traditional methods, he was intrigued.
“If you could identify those receptors that will direct the T cells to kill a tumor, amplify those cells in greater number outside the patient in a test tube, so to speak, and then reintroduce a healthy version of that T cell into the patient, you’ve essentially transcended what vaccines are hoping to do,” said Apelian, who was previously chief medical officer at GlobeImmune, one of the early leaders in cancer vaccines. “You’re getting right to the endpoint that you want.”
The overall approach also consists of a downstream program that utilizes BlueSphere’s NEOXpress platform, which will enable the individualization of treatments for specific cell tumors.
BlueSphere profiles tumor cells by DNA and RNA sequencing and identifies the neoantigen profile in those tumors. “In parallel, we’re extracting the T cells from that same tumor, we’re identifying the repertoire of TCRs, and then we’re marrying the two datasets up. It’s a multiplex approach,” Apelian said. Next, they will identify the ones that “light up,” characterize those T cell receptors and their ability to kill the tumor, and specifically recognize the target antigen but not the native antigen.
BlueSphere will put the platform to its first test late in 2022 with the planned launch of a clinical trial in bone marrow recipients with high-risk leukemia. Apelian shared that acute myeloid leukemia (ALL) is likely to be the lead indication in that program. Here, they will be targeting minor histocompatibility antigens.
When a high-risk AML patient has not responded to first-line therapy or failed a first bone marrow transplant, Apelian said the chance of a successful transplant is probably 10%—if that. While essentially a match, there are still many minor variations between a donor and recipient. This program aims to raise those odds.
“We can engineer a T cell into the donor cell, which the recipient is already getting anyway; we can eliminate all the other minor antigen variants, and then shift that to a leukemia-only response,” he explained. This enables complete engraftment, knocking out any residual leukemia cells along with the patient’s marrow and ultimately leading to improved long-term survival.
This is an example of an allogeneic, off-the-shelf target. On the other end of the spectrum, BlueSphere’s technology enables it to take a precise approach to each patient’s tumor.
Apelian explained that certain cancers called “hot tumors” possess a high number of different antigens. Melanoma probably has the most complex neoantigen profile because these tumors are caused by exposure to the sun, which allows more mutations to occur. Non-small-cell lung cancers also have a fair number of neoantigens.
“We can literally take a patient’s tumor and extract the tumor-specific antigens that patient has generated uniquely in their own tumor, and then identify the receptors to target the patient’s very own tumors,” Apelian said.
The benefit of this individualized therapy, he continued, is that “the patient’s body is already making those T cell receptors, so it’s very unlikely we’re going to make a receptor that’s going to be toxic to the patient.”
Then, BlueSphere can enrich these receptors, grow them in large quantities in a re-engineered healthy version of the T cell, and replace them in the patient’s body.
“Those T cells are sick; they’re exhausted. So, we’re taking that receptor part and re-engineering it into a healthy version of their own T cell, and then reintroducing it into the patient,” Apelian said. “That’s going to be the game-changer for solid tumors.”
Conversely, there are other cancers known as cold tumors. These include ovarian cancer, prostate cancer, pancreatic cancer, glioblastomas, and most breast cancers. Apelian believes his company’s platform has the throughput capability to tackle these as well.
“We think we have enough throughput with our TCXpress to even identify TCRs for those neoantigens in so-called cold tumors, but that’s kind of a downstream project for us,” he said.
In the middle of this range, BlueSphere will look at other exciting targets for solid tumors that can be re-engineered ahead of time to treat a myriad of different cancers.
While some elements of the work will be off-the-shelf, and there is a movement in the industry toward finding a universal cell, Apelian explained many advantages to the autologous approach.
“I understand the motivation for that [quest for a universal cell], but I think you’re going to lose a lot of the specificity and the elegance—the exquisite specificity of T cell,” he said. “We think it’s going to be more likely that autologous approaches and individualized therapies will be safer and more effective.”
BlueSphere is conducting what it calls the “virtual patient program” to determine the next steps in its pipeline. Instead of waiting to complete manufacturing aspects necessary for individualized tumor therapies, the company is building a tissue repository to test various tumors. Here, they will identify the neoantigen profile, extract the T cell repertoire from the tumor, and characterize the potential to recognize and kill the tumor.
“We’re collecting tissues, local tissues and some tissues from the National Cancer Institute, and we’re testing as if they were patients in a study,” Apelian explained.
He also expressed an interest in working collaboratively to solve cancers outside of BlueSphere’s purview and other diseases. “I could see this [technology] being useful a huge array of diseases that we can treat by appropriately re-engineering T cells to have the right T cell receptors,” he said.
With obvious ambition and belief in its platform, BlueSphere expects to double its workforce, which sits at 38 people, over the next 18 to 24 months.
“It’s a super exciting time for the company,” Apelian said, “It feels like moonshot startup excitement, which is fun. Everyone kind of appreciates how game-changing this platform could be.”
